We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Clinical Crossroads |

Celiac Disease Diagnosis and Management A 46-Year-Old Woman With Anemia

Daniel Leffler, MD, MS, Discussant
JAMA. 2011;306(14):1582-1592. doi:10.1001/jama.2011.1312.
Text Size: A A A
Published online

Celiac disease is one of the most prevalent autoimmune gastrointestinal disorders, but as the case of Ms J illustrates, diagnosis is often delayed or missed. Based on serologic studies, the prevalence of celiac disease in many populations is estimated to be approximately 1% and has been increasing steadily over the last 50 years. Evaluation for celiac disease is generally straightforward and uses commonly available serologic tests; however, the signs and symptoms of celiac disease are nonspecific and highly heterogeneous, making diagnosis difficult. Although celiac disease is often considered a mild disorder treatable with simple dietary changes, in reality celiac disease imparts considerable risks, including reduced bone mineral density, impaired quality of life, and increased overall mortality. In addition, a gluten-free diet is highly burdensome and can profoundly affect patients and their families. For these reasons, care of individuals with celiac disease requires prompt diagnosis and ongoing multidisciplinary management.

Figures in this Article

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?


Place holder to copy figure label and caption
Figure 1. Duodenal Biopsy Specimens
Graphic Jump Location

A, Duodenal biopsy specimen from Ms J's upper endoscopy showing villous shortening and an increased number of intraepithelial lymphocytes, consistent with celiac disease. B, Biopsy specimen of normal duodenum for comparison. Magnification ×200; hematoxylin-eosin stain.

Place holder to copy figure label and caption
Figure 2. Antigen Presentation and Production of Antibodies to Gluten Peptides and Tissue Transglutaminase (tTG)
Graphic Jump Location

In the subepithelium of the small intestine, native (partially digested) gluten peptides are deamidated by the enzyme tTG. While tTG is ubiquitous, it is predominantly stored intracellularly in an inactive state and released in the presence of inflammation and activated by higher levels of extracellular calcium ions. Deamidation leads to change in shape and charge of the gluten peptides, permitting high-affinity binding to HLA-DQ2 and -DQ8 on APCs such as dendritic cells and macrophages. Only HLA-DQ2 and -DQ8 are able to bind gluten peptides strongly enough to trigger an inflammatory reaction, so the presence of at least 1 of these molecules is a prerequisite for development of celiac disease. Naive T cells that have been activated by deamidated gluten presented by APCs are then able to stimulate both a TH1 cytotoxic and TH2 humoral antibody response. The TH2 response leads to production of antibodies against native gluten peptide, deamidated gluten peptide, and tTG. Antibodies to the self-protein tTG are produced because tTG is often still complexed with deamidated gluten peptides during presentation by APCs. This directed anti-self immune response is the major autoimmune component of celiac disease. TCR indicates T-cell receptor; IFN, interferon.

Place holder to copy figure label and caption
Figure 3. Pathophysiology of Celiac Disease and Potential Nondietary Therapies Being Tested in Phase 1 or 2 Clinical Trials
Graphic Jump Location

Gluten peptides are poorly digested by mammalian digestive enzymes and reach the small intestinal mucosa as large polypeptides. Gluten peptides are able to cross the mucosa into the subepithelium by transcellular and/or paracellular pathways. In the subepithelium, gluten peptides are deamidated by tissue transglutaminase (Figure 2) and trigger cytotoxicity leading to mucosal damage and humoral immunity leading to antibody production. Detailed understanding of the pathophysiology of celiac disease has allowed for creation of highly targeted potential nondietary therapies (blue boxes). These include (A) alteration of gluten-containing foods through the use of alternative or genetically modified wheat varieties or through specialized food processing techniques; (B) degradation of gluten proteins in the stomach and small intestinal lumen by selected proteases; (C) preventing gluten passage into the subepithelium of the small intestine through the use of tight junction agonists; and (D) reinduction of tolerance to gluten though immune desensitization.




You need to register in order to view this quiz.
Submit a Response
responses to the questions for readers
Posted on September 22, 2011
Oscar M Jolobe, Mb., ChB
Manchester Medical Society
Conflict of Interest: None Declared
Symptoms which should prompt testing for celiac disease include diarrhea(even when the latter is initially thought to be attributable to irritable bowel syndrome), weight loss, and dyspepsia(1), and symptoms of anemia such as lassitude and glossitis(2). Although the diagnosis is made most accurately by biopsy of the proximal small intestine(1)(3), a useful screening test is the documentation of serum IgA antibodies to tissue transglutaminase(1). Patients with IgA deficiency should be screened with an IgG test(1). In a comparison of test accuracy of transglutaminase autoantibodies(TGAA) across 20 participating laboratories it emerged that laboratory sensitivity ranged from 69% to 93%, and specificity ranged from 96% to 100%(4). Given the above observations(4), and the fact that "a small but significant number of cases of celiac disease will be missed by relying on serology alone"(3), all suspected cases should have histological confirmation. Populations that should be screened include first degree family members or other close relatives of patients with biopsy confirmed celiac disease. Other candidates are individuals with type 1 diabetes, autoimmune thyroid and adrenal disease, hepatobiliary disorders, Down syndrome, Turner syndrome(2). Screening tests(using TGAA) should be undertaken only if the individual is willing to undergo endoscopy with intestinal biopsy, and embark on gluten free diet if necessary. Genetic screening for HLA-DQ2 and HLA-DQ8 genes might be a useful additional strategy in family members who are suspected of having false negative TGAA, given the fact that the absence of the culprit genotype has a high negative predictive value for diagnosing celiac disease(2). Over and above adherence to a gluten-free diet, haematinic deficiencies(which may include iron, folate and vitamin B12) should be corrected(2). Vitamin D deficiency should be corrected, as should fluid and electrolyte deficits(2). Celiac disease that is refractory to gluten free diet might respond to immunosuppressive treatment(2)Adherence to a gluten free diet is mandatory and is never optional(2). In view of potential haematinic and vitamin deficiencies patients with celiac disease should be tested for these deficits, and, arguably also for diabetes, thyroid, and adrenal disease. Monitoring is primarily for documentation of symptom resolution, weight gain, and improvement in laboratory abnormalities. Monitoring is also for the purpose of evaluating adherence to gluten free diet, especially in non-responders. Non response despite dietary compliance should be an indication fro capsule endoscopy to evaluate complications such as ulcerative jejunitis and lymphoma(5) References
(1) Crowe SE Celiac Disease Annals of Internal Medicine 3rd May 2011;ITC-1 to ITC 14
(2) Cooke WT., Peeney ALP., Hawkins CF Symptoms, signs, and diagnostic features of idiopathic steatorroea Q J Med 1953 New Series XXII, No 85 59-77
(3) Sweis R., Pee L., Smith-Laing G Discrepancies between histology and serology for the diagnosis of coeliac disease in a district general hospital: is this an unrecognised problem in other hospitals? clinical Medicine 2009;9:346-8
(4) Li M., Yu L., Tiberti C et al A report on the international transglutaminase autoantibody workshop for celiac disease Am J Gastroenterol 2009;104:154-163
(5)Sidhu R., Sanders DS., Morris AJ., McAlindon ME Guidelines on small bowel enteroscopy and capsule endoscopy in adults GUT 2008;57:125-136
Conflict of Interest: None declared
Submit a Response


Some tools below are only available to our subscribers or users with an online account.

14 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

Related Multimedia

Author in the Room

audio player

Articles Related By Topic
PubMed Articles